Delving into the Latest Updates on MOR-107 with Synapse

Overview

Basic Info

Drug Type

Synthetic peptide

Synonyms

+ [3]

Target

AT2R

Action

agonists

Mechanism

AT2R agonists(Angiotensin II receptor type 2 agonists)

Therapeutic Areas

Endocrinology and Metabolic DiseaseUrogenital Diseases

Active Indication-

Inactive Indication

Diabetic Nephropathies

Originator Organization

MorphoSys AG

Active Organization-

Inactive Organization

LanthioPep BV

MorphoSys AG

Drug Highest PhaseDiscontinuedPhase 1

First Approval Date-

Regulation-

Login to view timeline

Background:Rheumatoid arthritis is a chronic autoimmune disease, progressively distinctive via cartilage destruction, auto-antibody production, severe joint pain, and synovial inflammation. Nanotechnology represents one of the utmost promising scientific technologies of the 21st century. Nanocarriers could be the key to unlocking its potential by encapsulating Rutin in targeted drug delivery systems, potentially for targeted Rheumatoid arthritis therapy.Objective:The rationale of current research is to prepare liposomes loaded with a bioflavonoid drug rutin for effective management of rheumatoid arthritis.Materials and Methods:This study investigated the formulation of rutin liposomes using the thinfilm hydration technique, also known as the Bangham method. A Box-Behnken design was employed to optimize the formulation parameters. The LP2 batch was then characterized for its mean particle size, zeta potential, shape, diffraction pattern, and thermal properties. Finally, the in-vitro anti-oxidant and anti-inflammatory potential of the rutin liposomes were evaluated using appropriate assays.Results:Out of thirteen batches, LP2 was found to be an optimized batch with a mean particle size of 167.1 nm, zeta potential -13.50 mV, and entrapment efficiency of 61.22%. The above results showed higher stability of rutin liposomes. Further characterization of LP2 for morphological assessment, XRD analysis, and DSC revealed its spherical shape less than 1 μm, polycrystalline nature, and thermographic peak at 139°C, respectively. Evaluation of the antioxidant properties and antiinflammatory potential of LP2 revealed its maximum therapeutic potential in the reduction of inflammation and protein denaturation when evaluated via in-vitro assays.Conclusion:Rutin liposomal formulation has tremendous potential for the management of Rheumatoid arthritis due to its enhanced bioavailability, anti-oxidant, and anti-inflammatory properties when compared to free rutin.

01 Jan 2025·International Journal of Biological Macromolecules

High modulus and strength polyurethane film synthesized from lignin-based polyol with various lignin contents and NCO/OH molar ratios

Article

Author: Zhang, Yongchao ; Wang, Mengmeng ; Tian, Guoyu ; Zhang, Yujie ; Fu, Yingjuan ; Liang, Jun ; Wang, Zhaojiang ; Wang, Changjian

This study explored the synthesis of lignin-polyol (LP) by liquefaction of Kraft lignin in polyethylene glycol and glycerol. LP23 (23 wt% lignin) and LP41 (41 wt% lignin) were obtained with remarkable liquefaction yields of 97.43 % and 93.75 %, respectively. LP-based polyurethane film (LP-PUF) was then fabricated by reacting LP23 and LP41 with hexamethylene diisocyanate. Mechanical properties and hydrophobicity of LP-PUF were optimized by varying NCO/OH molar ratios. LP23-PUF1.9 with NCO/OH of 1.9 showed excellent tensile strength of 34.28 MPa and Young's modulus of 233.27 MPa, while LP41-PUF2.0 with NCO/OH of 2.0 exhibited good tensile strength of 26.03 MPa and Young's modulus of 260.66 MPa. LP23-PUF2.0 displayed high hydrophobicity as indicated by the water contact angle of 96.8° and low surface free energy of 15.68 mN/m. Glass transition temperature (Tg) of LP-PUF varied depending on lignin content and NCO/OH molar ratio. Specifically, the increase of KL content from 23 % to 42 % induced big rise of Tg by 8 °C. The NCO/OH induced change of Tg was relatively weak, as indicated by the small increase of -2.71 °C of LP41-PU1.4 to -1.81 °C of LP41-PUF2.0. The results of this work offer insights for lignin utilization as structural component of high modulus and high strength polyurethane film.

01 Dec 2023·Peptides

AT2 receptor agonist LP2 restores respiratory function in a rat model of bleomycin-induced lung remodelling

Article

Author: Reichetzeder, Christoph ; Namsolleck, Pawel ; Villela, Daniel Campos ; Moll, Gert N

This study aimed to evaluate the prophylactic and therapeutic potential of angiotensin II type 2 receptor peptide agonist LP2 in bleomycin-induced airway and cardiac remodeling in rats. Male Wistar rats were intratracheally instillated with bleomycin. Animals of a prophylactic arm received LP2 from day 0 at intraperitoneal doses of 1, 3 or 10 μg/kg/d, whereas animals from a therapeutic arm received this LP2 treatment from day 7. On day 28 direct lung mechanics were determined and cardiac and lung tissues were collected and (histo)morphologically assessed. Prophylactic LP2 at 1 µg/kg/d with bleomycin, versus bleomycin alone, significantly improved the airway pressure responses at fixed inflation of 4 ml (p < 0.05) and 7 ml volume (p < 0.05), static compliance (p < 0.01), inspiratory capacity (p < 0.05), lung tolerance of increased volume (p < 0.0001), right to left ventricular hypertrophy (p < 0.05). Therapeutic regime showed a similar trend as the prophylactic arm but was less effective, mostly lacking significance. However, and importantly, therapeutic LP2 at 1 µg/kg/d significantly decreased mRNA expression of collagen 1A1 (p < 0.01), of Connective Tissue Growth Factor 1 (p < 0.05) and of Tissue MetalloPeptidase inhibitor 1 (p < 0.05). In conclusion, a very low dose of 1 µg/kg/d LP2 has capacity to counter bleomycin-induced impairment of lung functioning and consequent cardiac remodeling.

100 Deals associated with MOR-107

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetic Nephropathies	Phase 1	Germany	MorphoSys AG	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data